DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 103,501 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 72.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,885 shares of the specialty pharmaceutical company's stock after selling 103,501 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned approximately 0.07% of Supernus Pharmaceuticals worth $1,406,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Cubist Systematic Strategies LLC grew its position in shares of Supernus Pharmaceuticals by 944.2% during the 4th quarter. Cubist Systematic Strategies LLC now owns 139,522 shares of the specialty pharmaceutical company's stock valued at $5,045,000 after acquiring an additional 126,161 shares during the period. Centiva Capital LP bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $331,000. Brevan Howard Capital Management LP bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $272,000. Captrust Financial Advisors grew its position in shares of Supernus Pharmaceuticals by 84.6% during the 4th quarter. Captrust Financial Advisors now owns 17,394 shares of the specialty pharmaceutical company's stock valued at $629,000 after acquiring an additional 7,969 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock valued at $10,581,000 after acquiring an additional 208,552 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday.

Insider Activity

In related news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Stock Up 0.5%

Shares of Supernus Pharmaceuticals stock opened at $31.70 on Monday. The firm has a market cap of $1.77 billion, a PE ratio of 29.63 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company's fifty day simple moving average is $31.86 and its two-hundred day simple moving average is $34.90.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.